Thursday, May 25, 2017 6:20:08 PM
ISA investigation regarded "dissemination" of data.
So .... we all should understand that we have not invested in Pfizer .... Kitov is a Israeli nano cap with approx 5 employees and with very promising drugs, one of them a potential blockbuster that successfully passed phase 3. If you check the filing you could find out many reasons that could explain the delays .... the requested did by FDA in the pre-meeting NDA for example. In the meanwhile, after data results, during 2016, KIT-302 has been patented ....
What I'm trying to say you is that if you believed in KIT-302 and Waymack before, there is not reason you shouldn't now.
Kitov potential has been reviewed several time by Dexcel (that recently asked for filing a patent application together), by Kunhil Pharma and the last one by GHP partners (Gil Pogozelich recently sold a company he owned for more than $20mm), that accepted to sell Tyrnovo for Kitov shares and now owns 6,8% stake in Kitov (and this is not just an asset, this is science, years of work and research .... Alexander Levitzki says you something?) ....
More reasons to be optimistic. Lot of catalysts ahead.
All the best.
EnricoMania
FEATURED Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • Apr 22, 2024 8:49 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM